A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Fostamatinib (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Proof of concept; Therapeutic Use
- Acronyms SOAR
- Sponsors Rigel Pharmaceuticals
- 05 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2019.
- 05 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Apr 2019.
- 03 Oct 2017 Preliminary results of stage 1 are presented in the Rigel media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History